MX2019000660A - Compuestos, composiciones y métodos para el tratamiento de enfermedades. - Google Patents

Compuestos, composiciones y métodos para el tratamiento de enfermedades.

Info

Publication number
MX2019000660A
MX2019000660A MX2019000660A MX2019000660A MX2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A
Authority
MX
Mexico
Prior art keywords
compositions
compounds
methods
disease
treatment
Prior art date
Application number
MX2019000660A
Other languages
English (en)
Inventor
P Iyer Radhakrishnan
Sheri Anjaneyulu
Padmanabhan Seetharamaiyer
Meher Geeta
Zhou Shenghua
Challa Sreerupa
Cleary Dillon
H Gimi Rayomand
Original Assignee
Sperovie Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sperovie Biosciences Inc filed Critical Sperovie Biosciences Inc
Publication of MX2019000660A publication Critical patent/MX2019000660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Esta invención se refiere a compuestos y composiciones para la inducción de la expresión de un receptor de reconocimiento de patrones (por ejemplo, STING), y los métodos de uso de estos.
MX2019000660A 2016-07-15 2017-07-14 Compuestos, composiciones y métodos para el tratamiento de enfermedades. MX2019000660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363123P 2016-07-15 2016-07-15
US201662411405P 2016-10-21 2016-10-21
PCT/US2017/042106 WO2018013908A1 (en) 2016-07-15 2017-07-14 Compounds, compositions, and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2019000660A true MX2019000660A (es) 2019-10-02

Family

ID=60953343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000660A MX2019000660A (es) 2016-07-15 2017-07-14 Compuestos, composiciones y métodos para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (1) US20190292215A1 (es)
EP (1) EP3484504A4 (es)
JP (1) JP2019521138A (es)
KR (1) KR20190039522A (es)
CN (1) CN109715202A (es)
AU (1) AU2017295883A1 (es)
CA (1) CA3030830A1 (es)
CR (1) CR20190071A (es)
IL (1) IL264156A (es)
MX (1) MX2019000660A (es)
PH (1) PH12019500095A1 (es)
SG (1) SG11201900154VA (es)
WO (1) WO2018013908A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
AU2018364708A1 (en) 2017-11-10 2020-05-21 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチドおよびそのプロドラッグ
CA3145889A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
SG177564A1 (en) * 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
EP2611451A4 (en) * 2010-08-30 2014-01-15 Spring Bank Pharmaceuticals Inc DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS
KR20150119924A (ko) * 2013-02-18 2015-10-26 스프링 뱅크 파마슈티칼스, 인크. 백신 애쥬번트 및 치료제로서의 짧은 올리고뉴클레오티드의 설계
CN107148424B (zh) * 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
WO2017011622A1 (en) * 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors

Also Published As

Publication number Publication date
WO2018013908A1 (en) 2018-01-18
JP2019521138A (ja) 2019-07-25
AU2017295883A1 (en) 2019-02-21
CR20190071A (es) 2019-10-29
CN109715202A (zh) 2019-05-03
SG11201900154VA (en) 2019-02-27
PH12019500095A1 (en) 2019-10-28
US20190292215A1 (en) 2019-09-26
CA3030830A1 (en) 2018-01-18
EP3484504A4 (en) 2020-07-29
KR20190039522A (ko) 2019-04-12
IL264156A (en) 2019-02-28
EP3484504A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
PH12019500095A1 (en) Compounds, compositions, and methods for the treatment of disease
MX2022006260A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
CR20210508A (es) COMPUESTOS y COMPOSICIONES PARA EL TRATAMIENTO DE ENFERMEDAD
PH12015502788A1 (en) Antibody formulations and methods
GB2541571A (en) Pharmaceutical compositions
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EP3392348A3 (en) Method for selecting personalized tri-therapy for cancer treatment
PH12019500196A1 (en) Compounds and compositions and uses thereof
NZ732208A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
EA201792527A1 (ru) Лечение зуда
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX2016015298A (es) Inhibidores de nampt y metodos.
PH12017501872A1 (en) Methods of treating diseases
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
PH12019500038A1 (en) Compounds, compositions, and methods for the treatment of disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease